In a report released yesterday, Mara Goldstein from Mizuho Securities maintained a Buy rating on Merck & Company (MRK - Research Report), with a price target of $100.00. The company's shares closed last Friday at $87.34.According to TipRanks, Goldstein is a 3-star analyst with an average return of 2.7% and a 35.69% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Merck & Company, Incyte, and Adaptimmune Therapeutics.The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Merck & Company with a $100.00 average price target.
https://www.tipranks.com/news/blurbs/mizuho-securities-keeps-their-buy-rating-on-merck-company-mrk-2?utm_source=advfn.com&utm_medium=referral
Merck (NYSE:MRK)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more Merck Charts.